We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.38B
1-Year Est. Return
63.08%
This Fund
S&P 500
This Quarter
Est. Return
+16.95%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$1.52B
AUM Growth
-$7.28B
(-83%)
Cap. Flow
-$6.76B
Cap. Flow
% of AUM
-444.29%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
929
New
–
Increased
6
Reduced
3
Closed
920
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$184M |
| 2 |
First Horizon
FHN
|
+$107M |
| 3 |
SGFY
Signify Health, Inc.
SGFY
|
+$54.9M |
| 4 |
VMW
VMware, Inc
VMW
|
+$34.9M |
| 5 |
ONEM
1Life Healthcare
ONEM
|
+$29.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$572M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$456M |
| 3 |
Rogers Corp
ROG
|
+$432M |
| 4 |
AVLR
Avalara, Inc.
AVLR
|
+$373M |
| 5 |
SWCH
Switch, Inc. Class A Common Stock
SWCH
|
+$271M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.54% |
| 2 | Healthcare | 36.97% |
| 3 | Financials | 14.43% |
| 4 | Communication Services | 3.06% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Huntsman Corp
HUN
$1.78B
| – | – |
-155,050
| Closed | -$3.81M |
|
152
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.6B
| – | – |
-1,000,000
| Closed | -$2.59M |
|
153
Icon
ICLR
$12.4B
| – | – |
-6,510
| Closed | -$1.2M |
|
154
IDEAYA Biosciences
IDYA
$3.49B
| – | – |
-80,112
| Closed | -$1.2M |
|
155
Immunocore
IMCR
$1.75B
| – | – |
-34,697
| Closed | -$1.63M |
|
156
Immunic
IMUX
$198M
| – | – |
-19,799
| Closed | -$626K |
|
157
Insmed
INSM
$28.7B
| – | – |
-116,844
| Closed | -$2.52M |
|
158
Inspire Medical Systems
INSP
$1.7B
| – | – |
-14,300
| Closed | -$2.54M |
|
159
Invitation Homes
INVH
$18B
| – | – |
-350,796
| Closed | -$11.8M |
|
|
INZY
160
DELISTED
Inozyme Pharma
INZY
| – | – |
-165,498
| Closed | -$444K |
|
161
Ionis Pharmaceuticals
IONS
$9.06B
| – | – |
-54,497
| Closed | -$2.41M |
|
162
Iovance Biotherapeutics
IOVA
$2.77B
| – | – |
-202,872
| Closed | -$1.94M |
|
163
IQVIA
IQV
$38.3B
| – | – |
-18,504
| Closed | -$3.35M |
|
|
ITOS
164
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-57,500
| Closed | -$1.09M |
|
165
Jazz Pharmaceuticals
JAZZ
$16.7B
| – | – |
-59,040
| Closed | -$7.87M |
|
166
Jones Lang LaSalle
JLL
$16.7B
| – | – |
-7,024
| Closed | -$1.06M |
|
167
Johnson & Johnson
JNJ
$619B
| – | – |
-11,073
| Closed | -$1.81M |
|
168
Jet.AI
JTAI
$2.76M
| – | – |
-5
| Closed | -$2.4M |
|
169
KB Home
KBH
$3.49B
| – | – |
-21,077
| Closed | -$546K |
|
170
KBR
KBR
$4.74B
| – | – |
-57,801
| Closed | -$2.5M |
|
171
OrthoPediatrics
KIDS
$586M
| – | – |
-36,448
| Closed | -$1.68M |
|
172
Kiniksa Pharmaceuticals
KNSA
$5.97B
| – | – |
-140,962
| Closed | -$1.81M |
|
173
Karyopharm Therapeutics
KPTI
$44.2M
| – | – |
-18,081
| Closed | -$1.48M |
|
174
Kroger
KR
$35.1B
| – | – |
-25,000
| Closed | -$1.09M |
|
175
Kilroy Realty
KRC
$4.34B
| – | – |
-152,145
| Closed | -$6.41M |
|
Similar funds
FNBT
SAG
ACI
TCOV
RC
A
CGL
CB
UBS O'Connor's Q4 2022 Portfolio in Review
As of Q4 2022, UBS O'Connor held 929 positions worth $1.52B, down 83% from $8.8B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
UBS O'Connor withdrew a net $6.76B in Q4 2022, closing 920 positions and reducing 3 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.
By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.
Against the trend, UBS O'Connor added an estimated $184M to Horizon Therapeutics Public Limited Company Ordinary Shares.
- UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
- UBS O'Connor's biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $45.3M.
- UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
- UBS O'Connor's ten largest holdings make up 100% of its $1.52B portfolio in Q4 2022.
- UBS O'Connor opened 0 new positions and closed 920 in Q4 2022.
- UBS O'Connor's portfolio value fell 83% quarter-over-quarter to $1.52B.
Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.